You are here

layoffs

Daiichi Sankyo to cut 69 opioid sales jobs

Daiichi Sankyo to cut 69 opioid sales jobs

Beckers Hospital Review

Flag link:

Inovio axes staffers, cancer program to 'sharpen focus,' save cash

Inovio axes staffers, cancer program to 'sharpen focus,' save cash

Fierce Biotech

Flag link:

ImmunoGen cuts deep to eke out cash for mirvetuximab trial

ImmunoGen cuts deep to eke out cash for mirvetuximab trial

Fierce Biotech

Flag link:

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

Top analyst finds a silver lining in AbbVie’s $63B Allergan buyout — but there’s a catch

Endpoints

Flag link:

Conatus to Slash Staff, Consider Sale After NASH Trial Failures

Conatus to Slash Staff, Consider Sale After NASH Trial Failures

Xconomy

Conatus Pharmaceuticals

Flag link:

Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D

Sanofi to ax 466 jobs, step up focus on cancer, gene therapy R&D

Fierce Biotech

immuno-oncology

Flag link:

Sobi to buy Novimmune R&D assets, lay off 90 staff

Sobi to buy Novimmune R&D assets, lay off 90 staff

Fierce Biotech

Flag link:

Merrimack to Lay Off Remaining Execs and Staff, Sell Assets

Merrimack to Lay Off Remaining Execs and Staff, Sell Assets

BioSpace

Merrimack Pharmaceuticals

Flag link:

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

Troubled microbiome startup uBiome to lay off some employees, refund payments from federal insurers

Stat

Flag link:

Dynavax cuts staff in retreat from cancer research

Dynavax cuts staff in retreat from cancer research

Biopharma Dive

Dynavax Technologies

Flag link:

Merck plans to shed facilities, cut jobs in restructuring

Merck plans to shed facilities, cut jobs in restructuring

BioPharma Dive

drug manufacturing

Flag link:

Gilead cuts cardiopulmonary sales reps

Gilead cuts cardiopulmonary sales reps

BioCentury

Gilead Sciences

Flag link:

After revamping R&D in a global shakeup, Bayer prepping new labs for an expansion in cancer research at MIT

After revamping R&D in a global shakeup, Bayer prepping new labs for an expansion in cancer research at MIT

Endpoints

Flag link:

Merrimack zero for 3 as it dumps cancer drug over safety fears, axes staffers (again)

Merrimack zero for 3 as it dumps cancer drug over safety fears, axes staffers (again)

Fierce Biotech

Merrimack Pharmaceuticals

Flag link:

Recro Pharma to Lay Off 50 Following Second FDA Rejection for Non-Opioid Pain Treatment

Recro Pharma to Lay Off 50 Following Second FDA Rejection for Non-Opioid Pain Treatment

BioSpace

non-opioid pain treatments

Flag link:

Sanofi plans sales layoffs—again—in primary care, diabetes

Sanofi plans sales layoffs—again—in primary care, diabetes

Fierce Pharma

Flag link:

Obalon to lay off half its workforce in retail pivot

Obalon to lay off half its workforce in retail pivot

Mass Device

Flag link:

Janssen laying off 4 dozen employees as California plant heads toward closure

Janssen laying off 4 dozen employees as California plant heads toward closure

Fierce Pharma

drug manufacturing

Flag link:

First AbbVie chopped a PhIII, then they wrote off $4B in book value. Now 178 Stemcentrx workers are getting the ax

First AbbVie chopped a PhIII, then they wrote off $4B in book value. Now 178 Stemcentrx workers are getting the ax

Endpoints

Flag link:

Bayer to cut 200 jobs at U.S. logistics center as it alters course for pharma

Bayer to cut 200 jobs at U.S. logistics center as it alters course for pharma

Fierce Pharma

Flag link:

Pages